Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Gatsios Leaving Healthlinx; New COO at Agilent; and More

Premium

Healthlinx said this week that CEO Nick Gatsios will resign as of June 30, 2012.

Gatsios was a founding director of the company when it launched in 2002 and has been its CEO since it went public on the Australian Stock Exchange in 2006. He is extending his contracted notice period by two months in order “to complete current projects of strategic importance,” the company said.

No reason was given for his departure.


Agilent this week appointed Ron Nersesian executive vice president and chief operating officer.

Prior to the appointment, Nersesian had been president of Agilent’s Electronic Measurement Group.


Sparton Corporation’s board of directors this week named Charles Kummeth an independent director.

Kummeth is president of Thermo Fisher Scientific’s Global Chromatography and Mass Spectrometry division.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.